Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 4Gynecologic 3Breast 2Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Ovarian Neoplasms 15Neoplasms 3Sarcoma 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Uterine Neoplasms 1Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Recurrence 1Peritoneal Neoplasms 1Ovarian Epithelial Cancer Recurrent 1Ovarian Diseases 1Neurofibrosarcoma 1Neoplasms by Site 1Malignant mesenchymal tumor 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Genital Diseases, Female 1Gastrointestinal Stromal Tumors 1Fibrosarcoma 1Fanconi Anemia, Complementation Group D1 1Endocrine Gland Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma 1

Interventions

Paclitaxel 28Carboplatin 28pembrolizumab 25Bevacizumab 14liposomal doxorubicin 12Cisplatin 11Gemcitabine 10Radiotherapy 8Drug Therapy 8Cyclophosphamide 8Blood Specimen Collection 8Topotecan 7Nivolumab 7olaparib 6Doxorubicin 6niraparib 5Therapeutics 5Dexamethasone 5pertuzumab 4pazopanib 4lenvatinib 4fludarabine 4cemiplimab 4atezolizumab 4Trastuzumab 4Surveys and Questionnaires 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Fulvestrant 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × Trabectedin × Gynecologic × Clear all
NCT00786838 2014-04-11

A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
76 enrolled 17 charts
BreastGynecologicSarcoma

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Sarcoma

NCT00050414 2013-01-10

A Study of Trabectedin in Patients With Advanced Ovarian Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
147 enrolled
Gynecologic

Adnexal Diseases, Endocrine Gland Neoplasms, Genital Diseases, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms

NCT00050440 2013-01-08

Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
50 enrolled
Gynecologic

Carcinoma, Neoplasms, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡